Success Metrics

Clinical Success Rate
88.9%

Based on 16 completed trials

Completion Rate
89%(16/18)
Active Trials
4(14%)
Results Posted
25%(4 trials)
Terminated
2(7%)

Phase Distribution

Ph early_phase_1
2
7%
Ph not_applicable
2
7%
Ph phase_1
3
10%
Ph phase_2
8
28%
Ph phase_3
7
24%
Ph phase_4
5
17%

Phase Distribution

5

Early Stage

8

Mid Stage

12

Late Stage

Phase Distribution27 total trials
Early Phase 1First-in-human
2(7.4%)
Phase 1Safety & dosage
3(11.1%)
Phase 2Efficacy & side effects
8(29.6%)
Phase 3Large-scale testing
7(25.9%)
Phase 4Post-market surveillance
5(18.5%)
N/ANon-phased studies
2(7.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

16 of 20 finished

Non-Completion Rate

20.0%

4 ended early

Currently Active

4

trials recruiting

Total Trials

29

all time

Status Distribution
Active(6)
Completed(16)
Terminated(4)
Other(3)

Detailed Status

Completed16
Recruiting4
unknown3
Withdrawn2
Terminated2
Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials
29
Active
4
Success Rate
88.9%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (7.4%)
Phase 13 (11.1%)
Phase 28 (29.6%)
Phase 37 (25.9%)
Phase 45 (18.5%)
N/A2 (7.4%)

Trials by Status

recruiting414%
withdrawn27%
terminated27%
completed1655%
unknown310%
not_yet_recruiting27%

Recent Activity

Clinical Trials (29)

Showing 20 of 29 trialsScroll for more
NCT07435103Phase 1

Xenon Therapy for Children With Autism Spectrum Disorder

Not Yet Recruiting
NCT02220426Phase 1

Hyperpolarized Xenon-129 Magnetic Resonance Imaging and Spectroscopy of Brown Fat: Healthy Adult Volunteer Pilot Study

Terminated
NCT01043419Phase 1

Sympathetic Neural Outflow During Xenon Anesthesia in Humans

Completed
NCT00937807Phase 4

Hemodynamic Stability During Carotid Endarterectomy.Comparison of LENOXe™ (Xenon 100% v/v) Versus Sevoflurane

Completed
NCT06080100Early Phase 1

RELIEF OF PSYCHOEMOTIONAL STRESS USING XENON SEDATION

Recruiting
NCT03748446Early Phase 1

Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar Disorder

Recruiting
NCT04696523Phase 2

Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage

Recruiting
NCT03176186Phase 3

Xenon for Neuroprotection During Post-Cardiac Arrest Syndrome in Comatose Survivors of an Out of Hospital Cardiac Arrest

Not Yet Recruiting
NCT04793867

Regional Phenotyping of CF and Non-CF Bronchiectasis

Recruiting
NCT05335109Phase 3

Neuroprotective Effects of Xenon Treatment in Patients with Cerebral Infarction

Completed
NCT02768727Phase 2

A Test of Neural Inertia in Humans With Xenon

Completed
NCT04432155Phase 2

Xenon Inhalation for Treatment of Panic Disorder

Unknown
NCT03504033Phase 4

Xenon-anesthesia on Patients Undergoing Major Liver-resection

Withdrawn
NCT03968861

Outcome After 24 Months of Participants in the TOBY Xenon Study

Completed
NCT02682758Phase 4

Influence of Xenon Anaesthesia on Transpulmonary Pressure and Tidal Volume Distribution

Completed
NCT02468531Not Applicable

Xenon Against Postoperative Oxygen Impairment

Unknown
NCT01696630Phase 2

Xenon Combined With Intraoperative Thoracic Epidural Analgesia

Completed
NCT02774096Not Applicable

Cerebral and Spinal Protection of Xenon Post-conditioning in Patients Undergoing Aortic Dissection Repair

Unknown
NCT01839084Phase 3

PaNeX: Partial Nephrectomy Under Xenon

Completed
NCT01294163Phase 3

Xenon Compared to Sevoflurane and Total Intravenous Anaesthesia for Coronary Artery Bypass Graft Surgery

Completed

Drug Details

Intervention Type
DRUG
Total Trials
29